Compare · CLVR vs NVO
CLVR vs NVO
Side-by-side comparison of Clever Leaves Holdings Inc. (CLVR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLVR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 3547.1x CLVR ($51.6M).
- NVO has hit the wire 8 times in the past 4 weeks while CLVR has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 4 for CLVR).
- Company
- Clever Leaves Holdings Inc.
- Novo Nordisk A/S
- Price
- $2.99+40.38%
- $41.01-4.51%
- Market cap
- $51.6M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 4
- 25
Clever Leaves Holdings Inc.
Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company operates through two segments, Cannabinoid and Non-Cannabinoid. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors. Clever Leaves Holdings Inc. is based in New York, New York.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CLVR
- New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)
- SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)
- SEC Form 15-12G filed by Clever Leaves Holdings Inc.
- SEC Form SC 13D filed by Clever Leaves Holdings Inc.
- SEC Form EFFECT filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form S-8 POS filed by Clever Leaves Holdings Inc.
- SEC Form POS AM filed by Clever Leaves Holdings Inc.
- SEC Form 25 filed by Clever Leaves Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care